Antibodies and methods for the diagnosis and treatment of Epstein Barr Virus infection

Patent metadata

Field	Value
Publication number	US-11926656-B2
Application number	US-202117553139-A
Country	US
Kind code	B2
Filing date	Dec 16, 2021
Priority date	Apr 25, 2017
Publication date	Mar 12, 2024
Grant date	Mar 12, 2024

Abstract

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

First claim

The invention claimed is:

1. A protein comprising:
a polypeptide sequence at least 85% identical to the amino acid sequence of the complement receptor 2 (CR2)-binding region of Epstein-Barr virus (EBV) gp350 set forth as amino acid residues 2-425 of SEQ ID NO: 124, wherein the amino acid residue corresponding to amino acid D296 of SEQ ID NO: 124 is substituted with arginine,
wherein the protein can bind an anti-gp350 antibody, or a B-cell expressing an anti-gp350 B-cell receptor (BCR), wherein binding of the B-cell is through the BCR, and wherein binding of the protein to CR2 is substantially reduced compared binding of wild-type gp350 to CR2.

2. The protein of claim 1 , wherein the polypeptide sequence is at least 90% identical to amino acid residues 2-425 of SEQ ID NO: 124, wherein the amino acid residue corresponding to amino acid D296 of SEQ ID NO: 124 is substituted with arginine.

3. The protein of claim 1 , wherein the amino acid corresponding to amino acid Q122 of SEQ ID NO: 124 is substituted with asparagine, methionine, leucine, isoleucine, glycine, alanine, valine, phenylalanine, tyrosine, tryptophan, lysine, arginine, histidine, glutamate, or aspartate.

4. The protein of claim 1 , wherein the amino acid corresponding to amino acid P158 of SEQ ID NO: 124 is substituted with arginine, methionine, leucine, isoleucine, glycine, alanine, valine, phenylalanine, tyrosine, tryptophan, lysine, histidine, glutamate, or aspartate.

5. The protein of claim 1 , wherein the amino acid corresponding to amino acid I160 of SEQ ID NO: 124 is substituted with arginine, serine, threonine, cysteine, proline, asparagine, glutamine, tyrosine, phenylalanine, tryptophan, glutamate, aspartate, glutamine, histidine, or lysine.

6. The protein of claim 1 , wherein the amino acid corresponding to amino acid W162 of SEQ ID NO: 124 is substituted with alanine, serine, threonine, cysteine, proline, asparagine, glutamine, aspartate, glutamate, asparagine, arginine, glutamate, histidine, glycine, valine, leucine, methionine, isoleucine, or lysine.

7. The protein of claim 1 , wherein the amino acid corresponding to amino acid D163 of SEQ ID NO: 124 is substituted with asparagine, tyrosine, phenylalanine, tryptophan, serine, threonine, cysteine, proline, glutamine, lysine, arginine, histidine, glycine, alanine, valine, leucine, methionine, or isoleucine.

8. The protein of claim 1 , wherein the amino acid corresponding to amino acid N164 of SEQ ID NO: 124 is substituted with serine, methionine, leucine, isoleucine, glycine, alanine, valine, phenylalanine, tyrosine, tryptophan, lysine, arginine, histidine, glutamate, or aspartate.

9. The protein of claim 1 , wherein the amino acid corresponding to amino acid K161 of SEQ ID NO: 124 is substituted with methionine, leucine, isoleucine, glycine, alanine, valine, phenylalanine, tyrosine, tryptophan, lysine, arginine, histidine, glutamate, serine, or aspartate.

10. The protein of claim 1 , wherein the amino acid corresponding to amino acid P158 of SEQ ID NO: 124 is substituted with arginine; and the amino acid corresponding to amino acid I160 of SEQ ID NO:124 is substituted with arginine.

11. The protein of claim 1 , wherein a serine, threonine, cysteine, proline, asparagine, or glutamine residue is inserted between the amino acid corresponding to amino acid N164 of SEQ ID NO: 124 and the amino acid corresponding to C165 of SEQ ID NO: 124.

12. The protein of claim 1 , wherein the amino acids corresponding to amino acids W162-N164 of SEQ ID NO: 124 are each substituted with an alanine residue.

13. The protein of claim 1 , wherein the protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 131, SEQ ID NO: 135, SEQ ID NO: 137, SEQ ID NO: 139, SEQ ID NO: 141, SEQ ID NO: 149, SEQ ID NO: 153, SEQ ID NO: 155, SEQ ID NO: 157 and SEQ ID NO: 159.

14. A nucleic acid molecule encoding the protein of claim 13 .

15. A nucleic acid molecule encoding the protein of claim 1 .

16. A method for identifying an anti-gp350 antibody, or an anti-gp350 B cell, comprising: contacting the protein of claim 1 with a solution comprising antibodies or B cells; and isolating antibodies or B cells that specifically bind to the protein.

17. The protein of claim 1 , wherein the polypeptide sequence consists of amino acid residues 2-425 of SEQ ID NO: 124, wherein the amino acid residue corresponding to amino acid D296 of SEQ ID NO: 124 is substituted with arginine.

18. A nucleic acid molecule encoding the protein of claim 17 .

19. The protein of claim 1 , wherein the polypeptide sequence consists of amino acid residues 2-425 of SEQ ID NO: 124, wherein amino acid residue corresponding to amino acid D296 of SEQ ID NO: 124 is substituted with arginine and the amino acid corresponding to amino acid I160 of SEQ ID NO: 124 is substituted with arginine.

20. A nucleic acid molecule encoding the protein of claim 19 .

Assignees

• Us Health
• Henry M Jackson Found Advancement Military Medicine Inc
• Us Health

Inventors

• Bu Wei
• Kanekiyo Masaru
• Joyce Michael Gordon
• Cohen Jeffrey I

Classifications

• C07K16/085 Primary

  Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus · CPC title

• C07K14/05

  Epstein-Barr virus · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2317/10

  characterized by their source of isolation or production · CPC title

• C07K2317/21

  from primates, e.g. man · CPC title